Boundless Bio Inc Dossier
Qualitative Analysis
Business overview
Boundless Bio, Inc. (NASDAQ: BOLD) is a clinical-stage precision oncology company wholly dedicated to developing innovative therapeutics directed against extrachromosomal DNA (ecDNA). ecDNA is a primary driver of oncogene amplification and is observed in up to 40% of metastatic cancers, where it promotes tumor growth, metabolic adaptation, and rapid resistance to standard targeted therapies and immunotherapies. Normal healthy tissues do not contain ecDNA, making it a highly selective therapeutic target. Leveraging its proprietary Spyglass platform, Boundless Bio identifies essential cellular machinery required for ecDNA replication, segregation, and transcription, and designs small-molecule ecDNA-directed therapeutic candidates (ecDTx) to selectively eliminate ecDNA-positive cancer cells.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Boundless Bio streamlined its clinical pipeline to focus resources primarily on BBI-940, its first-in-class oral Kinesin degrader that directly targets ecDNA segregation and inheritance during mitosis. As part of this strategic pivot, the company ceased enrollment in the Phase 1/2 POTENTIATE trial (evaluating the BBI-355 and BBI-825 combination) to optimize capital allocation.
Expected impact: Extends the company's cash runway into the second half of 2028 and concentrates clinical efforts on its most promising direct ecDNA-targeting asset.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Co-development of the ecDNA Solution (ECS) algorithm, based on Boundless Bio's proprietary ECHO (ecDNA Harboring Oncogenes) diagnostic algorithm. This clinical trial assay detects the presence of oncogenes amplified on ecDNA using routine next-generation sequencing (NGS) data, enabling precise patient selection for clinical trials.
Terms: Terms not publicly disclosed.
Lilly provides its CDK4/6 inhibitor Verzenio (abemaciclib) at no cost for use in combination with Boundless Bio's BBI-355 in the POTENTIATE clinical trial for patients with CDK4 or CDK6 amplified solid tumors.
Terms: Lilly provides clinical drug supply at no cost; no direct financial obligations or cash transfers are involved.
Taiho provides its pan-FGFR inhibitor Lytgobi (futibatinib) at no cost for use in combination with BBI-355 in the POTENTIATE clinical trial for patients with FGFR-amplified solid tumors.
Terms: Taiho provides clinical drug supply at no cost; no direct financial obligations or cash transfers are involved.